Consumers say that smaller doses of a popular weight-loss drug eased side effects and improved their health Telehealth ...

Semaglutide’s U.S. patents keep generics out until around 2031 or 2035, maintaining Novo Nordisk’s exclusivity and high ...

The funding aims to encourage innovation in Europe amid concerns that innovation across the continent is lagging behind China ...

The Novo Nordisk Foundation has allocated up to DKK 5.5 billion (EUR 736 million) to BioInnovation Institute (BII), a leading ...

Compounding pharmacy sues Eli Lilly and Novo Nordisk alleging antitrust violations to restrict compounded GLP-1 medication access and limit competition.

Delaware sues drugmakers PBMs alleging a 15-year conspiracy to inflate insulin prices, impacting uninsured residents with diabetes.

Strive Compounding Pharmacy alleged in its lawsuit that Eli Lilly and Novo Nordisk have worked to lock telehealth providers ...

Drugmakers Eli Lilly and Novo Nordisk have been sued in Texas by a compounding pharmacy that alleges they are illegally ...

Years after approving three glucagon-like peptide-1 (GLP-1) receptor agonists to treat obesity, the U.S. FDA is acknowledging that the drugs don’t have the same risk seen with older weight-loss ...

The Novo Nordisk Foundation announced it was giving an additional $850 million to an institute to help commercialize ...

The Novo Nordisk Foundation is investing 5.5 billion Danish kroner ($860 million) in the BioInnovation Institute (BII) to help scale up more homegrown biotechs and deep tech companies. | The Novo ...

A compounding pharmacy has filed a lawsuit accusing Eli Lilly and Novo Nordisk of using anticompetitive tactics to prevent it ...